Phase 1 Study to Evaluate the Safety, Tolerability, and Immunogenicity of Hantaan and Puumala Virus DNA Vaccines, pWRG/HTN-M(x) and pWRG/PUU-M(s2), for Prevention of Hemorrhagic Fever With Renal Syndrome Administered to Healthy Adult Volunteers Using the TDS-IM Electroporation Delivery Device.
Latest Information Update: 13 Dec 2024
Price :
$35 *
At a glance
- Drugs PWRG-HTN-M(co) (Primary) ; PWRG-HTN-M(co)/pWRG-PUUV-M(s2) (Primary)
- Indications Hantaan virus infections; Puumala virus infections; Viral haemorrhagic fevers
- Focus Adverse reactions
- 10 Dec 2024 According to the PharmaJet Media Release, the results from this trial published in Nature.
- 01 Jan 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 27 Aug 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.